Elsevier Launches International Journal for Parasitology: Drugs and Drug Resistance

New open access journal dedicated to collaborations and cutting-edge research in Parasitology

Amsterdam, June 22, 2011 – Elsevier, a world-leading provider of scientific, technical and medical information products and solutions, in association with the  Australian Society for Parasitology, is pleased to announce the launch of a new journal,International Journal for Parasitology: Drugs and Drug Resistance. The new electronic open access journal is closely affiliated with the leading parasitology journal, International Journal for Parasitology, and will address a critical area of research, covering anti-parasite drug identification, development and evaluation, and parasite drug resistance. The journal’s remit also includes research into natural products as anti-parasitic agents, and bioactive parasite products.

Professor Terry Spithill, President of the Australian Society for Parasitology, said, “The Society is delighted to have fostered the founding of this new Journal which we anticipate will provide a stellar forum for the dissemination of original discoveries in the pharmacological control of parasites of human and veterinary significance.”

Original research includes the development of novel and innovative concepts and ideas, as well as experimental and observational science that raises new hypotheses. The Journal encourages critical comment and debate on matters of current controversy in the area of parasite drug resistance and anti-parasite drugs via "Current Opinions". Studies can be aimed at unicellular or multicellular parasites of human or veterinary importance.

“We are delighted to continue our excellent relationship with the Australian Society for Parasitology, and are confident that IJP:DDR will quickly establish itself as the leading journal in its field,” added Dale Seaton, Executive Publisher for Elsevier. “In addition, by utilizing the open access model option for this title, Elsevieris enabling the broadest possible access to quality research content in a sustainable way that meets the society’s needs.”

More information about the scope of articles accepted for submission are available on the  Journal’s website. Article submissions for IJP:DDR can be made at  http://ees.elsevier.com/ijpddr/

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Harald Boersma
Senior Manager, Corporate Relations, Elsevier
H.boersma@elsevier.com
+31 20 485 27 36